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an RTI and received a new prescription for one of the fol-
lowing antibiotics: amoxicillin, amoxicillin/clavulanate,
azithromycin, cefaclor, cefuroxime, ciprofloxacin, clarithro-
mycin or erythromycin. Patients were asked to complete
a self-administered quality of life questionnaire (QLQ-
C30) on day 1, 3, 7 and 14. They were also asked to indi-
cate their perception of their health status on a rating
scale. RESULTS: Of 989 patients recruited, 777 returned
their questionnaire (79%). Scores for the global health
status scale of the QLQ-C30 were expressed on a scale of
0 to 100 where 100 corresponds to a high global health
status. Mean score was 47 (sd  24) on day 1, 60 (sd 
20) on day 3, 74 (sd  19) on day 7 and 83 (sd  17) on
day 14. Improvement from day 1 to 14 varied according
to the antibiotic prescribed (ANOVA, P  0.04), how-
ever post-hoc analysis did not reveal any pairwise signifi-
cant difference (Scheffe, P  0.05). Results from the rat-
ing scale were strongly correlated with those obtained
with the global health status scale of the quality of life
questionnaire. CONCLUSION: RTIs have a definite im-
pact on patients’ quality of life, particularly on the first
few days. Quality of life steadily improves during the
course of the treatment.
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OBJECTIVE: To ascertain whether a change in co-amox-
yclav (A/C) market share was associated with changes in
patient outcomes in otitis media, sinusitis, lower respira-
tory infection and acute exacerbation of chronic obstruc-
tive airways disease. METHODS: An integrated database
of computerised records from four general practices,
based in 3 Australian States was collated for the period
mid-1994 to mid-1998. The database consisted of
34,242 patients and 318,234 notes. Conditions of inter-
ests and identifiable patient outcomes were sought. After
identification of the change in A/C market share using
segmented regression, a time series analyses was com-
pleted to define the relationship between the A/C market
share and rate of patient outcomes per encounter. The
A/C and all antibiotic market shares, the number of epi-
sodes of care (EOC) for the chosen conditions, the antibi-
otics prescribed and the patient casemix were measured.
The patient outcomes chosen included hospitalization,
referral to a specialist, CT scan of sinus and of chest,
chest x-ray, any pathology tests, spirometry, bronchos-
copy and sinoscopy. RESULTS: In total there were
11,378 EOC for all specified problems. 1082 people had
been given A/C for at least one EOC and 5879 other anti-
biotics. The casemix profile for both groups was similar.
The total number of negative outcomes were 1873, com-
prising 126 hospitalizations, 351 referrals, 794 radiology
investigations, 561 pathology tests and 41 other investi-
gations. The time series analyses revealed that for every
1% reduction in A/C market share, there was a 0.5 % in-
crease in negative outcomes, with a three month lag. The
3-month lag was the most significant (P  0.0001). The
decrease in A/C market share was related to an increase
in weighted costs of negative outcomes (P  0.0024).
CONCLUSIONS: A statistical, temporal association was
found between a fall in A/C market share among the
study GPs and a rise in negative patient outcomes.
PHV27
COSTS AND OUTCOMES OF TREATING FEBRILE 
NEUTROPENIA IN NINE EUROPEAN 
COUNTRIES
Flynn J1, Elixhauser A3, Constenla D1, Baleva J2, Ciuryla V2
1MEDTAP International, Bethesda, MD, USA; 2Wyeth-Ayerst, 
St. Davids, PA, USA; 3 Agency for Healthcare Research and 
Quality, Rockville, MD, USA
OBJECTIVES: The purchase price of antibiotics is often
an overriding factor in making acquisition or formulary
decisions. However, the economic consequences of using
drugs also include the costs of treatment failure and side
effects, e.g. additional therapies, tests, procedures, spe-
cialists, and hospitalization. This study evaluated the
costs and outcomes of antibiotic therapy for febrile neu-
tropenia in 9 European countries. METHODS: A model
was developed based on data from two clinical trials
comparing either the high- or low-dose regimen of piper-
acillin/tazobactam  amikacin versus ceftazidime  ami-
kacin. Clinical trial data provided the dosage, efficacy,
mortality and days with fever. Practice pattern data, in-
cluding duration of treatment and length of stay, were
provided by 3–6 clinicians in each country. Cost informa-
tion on drugs, hospital resource use and outpatient fol-
low-up care was obtained from primary and secondary
data sources in each country. Prices were expressed in
1995 currency and converted to US dollars and Euros for
comparison. RESULTS: Piperacillin/tazobactam  ami-
kacin was more effective than ceftazidime  amikacin for
both dosage regimens, resulting in fewer first-line therapy
failures, reduced number of hospital days and lower mor-
tality. Despite slightly higher daily drug costs for the piper-
acillin/tazobactam regimen, in 17 of 18 scenarios modeled
average total treatment costs were lower for piperacillin/
tazobactam than for the ceftazidime regimens for both
the high-dose and low-dose formulations in all 9 coun-
tries. CONCLUSIONS: In the treatment of febrile neu-
tropenia, piperacillin/tazobactam  amikacin was more
effective and less costly than ceftazidime  amikacin
when total treatment costs were considered. Thus piper-
acillin/tazobactam dominates its alternative, with similar
results across all 9 countries.
